Literature DB >> 30060960

Respiratory rate in infants with cystic fibrosis throughout the first year of life and association with lung clearance index measured shortly after birth.

Insa Korten1, Elisabeth Kieninger2, Sophie Yammine2, Giulia Cangiano3, Sylvia Nyilas4, Pinelopi Anagnostopoulou2, Florian Singer2, Claudia E Kuehni5, Nicolas Regamey6, Urs Frey7, Carmen Casaulta2, Ben D Spycher8, Philipp Latzin9.   

Abstract

BACKGROUND: Lung impairment in cystic fibrosis (CF) starts in infancy. However, tools to monitor early lung disease are limited. Respiratory rate (RR) as a key vital sign is easy to assess during sleep and is elevated during acute respiratory disease. Thus, elevated RR could indicate early lung impairment and potentially serve as a diagnostic tool in disease monitoring.
METHODS: In a prospective cohort of infants with CF diagnosed by newborn screening and healthy controls RR was measured and respiratory symptoms reported weekly throughout infancy. Infants performed a lung function measurement within the first weeks of life.
RESULTS: The analyses included 5656 measurements from 153 infants (43 with CF). RR declined from 43.2 (40.5)/min at 6 weeks of age to 28.3 (24.6)/min at 50 weeks in infants with CF (healthy controls). Infants with CF had consistently higher RR than controls (mean difference: 4.15/min; (95% CI 2.86-5.44); p < .001). In both study groups, RR was increased throughout the study period in infants with higher lung clearance indices (LCI) and during episodes of respiratory infections.
CONCLUSIONS: Infants with CF have a higher RR compared to healthy controls during the first year of life. The association with early LCI measurements, the current gold standard to assess physiology of peripheral airways persisted throughout the study period. This may indicate tracking of lung function by RR. It might thus be an early subtle sign of functional respiratory deficit. Further studies will show if RR can be used as a sensitive and promising marker to monitor early CF lung disease.
Copyright © 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Infancy; Infant lung function; Lung clearance index; Respiratory rate

Mesh:

Year:  2018        PMID: 30060960     DOI: 10.1016/j.jcf.2018.07.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

1.  Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system.

Authors:  Svenja Straßburg; Carolin-Maria Linker; Sebastian Brato; Christoph Schöbel; Christian Taube; Jürgen Götze; Florian Stehling; Sivagurunathan Sutharsan; Matthias Welsner; Gerhard Weinreich
Journal:  BMC Pulm Med       Date:  2022-02-11       Impact factor: 3.317

Review 2.  Sleep disorders in cystic fibrosis: A systematic review and meta-analysis.

Authors:  Joel Reiter; Alex Gileles-Hillel; Malena Cohen-Cymberknoh; Dennis Rosen; Eitan Kerem; David Gozal; Erick Forno
Journal:  Sleep Med Rev       Date:  2020-02-19       Impact factor: 11.609

Review 3.  Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing.

Authors:  Elpis Hatziagorou; Asterios Kampouras; Vasiliki Avramidou; Ilektra Toulia; Elisavet-Anna Chrysochoou; Maria Galogavrou; Fotios Kirvassilis; John Tsanakas
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

Review 4.  Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota.

Authors:  Wolfgang Bernhard
Journal:  Eur J Nutr       Date:  2020-08-14       Impact factor: 5.614

5.  Hyperinflation is associated with increased respiratory rate and is a more sensitive measure of cystic fibrosis lung disease during infancy compared to forced expiratory measures.

Authors:  Heather N Muston; James E Slaven; Christina Tiller; Charles Clem; Thomas W Ferkol; Sarath Ranganathan; Stephanie D Davis; Clement L Ren
Journal:  Pediatr Pulmonol       Date:  2021-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.